iRadimed (NASDAQ:IRMD) Stock Crosses Above 50 Day Moving Average – What’s Next?

iRadimed Corporation (NASDAQ:IRMD – Get Free Report) shares passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $85.29 and traded as high as $86.17. iRadimed shares last traded at $85.35, with a volume of 115,215 shares.

Analyst Upgrades and Downgrades

IRMD has been the topic of a number of recent analyst reports. Needham & Company LLC began coverage on shares of iRadimed in a research note on Tuesday, September 22nd. They issued a “hold” rating on the stock. Weiss Ratings raised shares of iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 16th. Finally, Wall Street Zen downgraded iRadimed from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, iRadimed currently has an average rating of “Buy” and a consensus price target of $120.00.

View Our Latest Report on IRMD

iRadimed Trading Up 0.1%

The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of 45.64 and a beta of 0.91. The company has a 50-day moving average of $85.29 and a 200-day moving average of $91.86.

iRadimed (NASDAQ:IRMD – Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.55. The firm had revenue of $24.20 million for the quarter, compared to analysts’ expectations of $23.47 million. iRadimed had a return on equity of 23.90% and a net margin of 26.85%. On average, research analysts forecast that iRadimed Corporation will post 1.92 earnings per share for the current year.

iRadimed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 27th. Stockholders of record on Friday, November 13th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Friday, November 13th. iRadimed’s dividend payout ratio (DPR) is presently 42.78%.

Insider Activity at iRadimed

In other news, Director Monty K. Allen sold 1,419 shares of iRadimed stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total value of $122,615.79. Following the completion of the transaction, the director directly owned 19,581 shares of the company’s stock, valued at approximately $1,691,994.21. The trade was a 6.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 34.60% of the company’s stock.

Hedge Funds Weigh In On iRadimed

A number of large investors have recently bought and sold shares of IRMD. Integrated Wealth Concepts LLC bought a new position in shares of iRadimed during the second quarter valued at approximately $28,000. IFP Advisors Inc lifted its holdings in shares of iRadimed by 264.7% in the 2nd quarter. IFP Advisors Inc now owns 569 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 413 shares during the last quarter. Global Retirement Partners LLC bought a new stake in shares of iRadimed in the 2nd quarter worth approximately $84,000. Inspire Investing LLC lifted its holdings in shares of iRadimed by 13.1% in the 3rd quarter. Inspire Investing LLC now owns 1,421 shares of the medical equipment provider’s stock worth $123,000 after purchasing an additional 165 shares during the last quarter. Finally, State of Wyoming bought a new stake in shares of iRadimed in the 2nd quarter worth approximately $130,000. Institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

(Get Free Report)

iRadimed Corporation develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. Its products include MRI-compatible patient monitoring systems and intravenous infusion pumps, along with related accessories. The company’s monitoring systems help clinicians track patients during MRI procedures, while its infusion pumps deliver fluids and medications in the MRI suite. iRadimed’s equipment is designed to operate in the presence of MRI magnets, where conventional medical devices may not be suitable.

Featured Articles

Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.